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C-Type Lectin-Like Receptors of the Dectin-1
Cluster: Ligands and Signaling Pathways
Anthony Plato, Janet A. Willment, and Gordon D. Brown
Aberdeen Fungal Group, Section of Immunology and Infection, University of Aberdeen,
Aberdeen, UK
Innate immunity is constructed aroundgenetically encoded receptors that survey the intracellular
and extracellular environments for signs of invading microorganisms. These receptors recognise
the invader and through complex intracellular networks of molecular signaling, they destroy the
threat whilst instructing eﬀective adaptive immune responses. Many of these receptors, like the
Toll-like receptors in particular, are well-known for their ability to mediate downstream responses
upon recognition of exogenous or endogenous ligands; however, the emerging family known as
the C-type lectin-like receptors containsmanymembers that have a huge impact on immune and
homeostatic regulation. Of particular interest here are the C-type lectin-like receptors that make
up the Dectin-1 cluster and their intracellular signalingmotifs that mediate their functions. In this
review, we aim to draw together current knowledge of ligands, motifs and signaling pathways,
present downstream of Dectin-1 cluster receptors, and discuss how these dictate their role within
biological systems.
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INTRODUCTION
Cells of the innate immune system possess an array of germ-line encoded receptors
that are essential for mounting an effective immune response to pathogens. Upon
pathogen recognition, these receptors initiate and instruct innate and adaptive
immune responses, ultimately leading to the containment and destruction of the in-
vading organisms. Interestingly, many receptors have identified self-ligands and play
important roles in the control of homeostasis [1, 2]. These receptors are expressed by
the host as transmembrane and cytoplasmic proteins and act to communicate stimuli
of foreign origin to cytoplasmic signaling cascades. They are known as pattern recog-
nition receptors (PRRs) and, as hypothesised by Charles Janeway, are characterised
by their ability to bind evolutionary-conservedmotifs present on pathogens [3].These
PRRs have been divided into four families: the Toll-like receptors (TLRs), nucleotide-
oligomerisation domain (NOD)-like receptors (NLRs), retinoic acid-inducible gene-1
(RIG-1)-like receptors (RLRs) and theC-type lectin-like receptors (CTLRs). Targets for
these receptors include cell wall components such as carbohydrates, yet recognisable
structures can include proteins, lipids and nucleic acids to name a few. Recognition
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of these conserved microbial motifs, also known as pathogen-associated molecular
patterns (PAMP), allows the host to detect non-self molecules and trigger immune
defences [4]. Secreted PRRs also exist and are able to modulate, but not directly
induce, anti-microbial inflammatory responses. However, in this review, we will only
focus on the PRRs able to directly induce intracellular signaling events.
Receptor activation following pathogen recognition on cell types such as dendritic
cells (DCs) induces intracellular signaling that can trigger several cellular responses,
including phagocytosis of the receptor-bound pathogen and induction of various
patterns of cytokine and chemokine expression, which in turn modulate innate
and adaptive inflammatory responses. Phagocytosis is an intricate process involving
receptor-mediated signaling cascades aswell as actin cytoskeleton remodelling.Upon
internalisation of the pathogen into a vacuole known as the phagosome, the phago-
some matures into an increasingly anti-microbial compartment through increasing
hydrolytic enzymes and toxic metabolite concentrations as well as reduction of inter-
nal pH.Othermechanisms involved include the respiratory burst pathways,where the
activation of themultimeric enzyme NADPH oxidase along with its translocation into
the phagosomemembrane reduces O2 forming reactive oxygen species (ROS) such as
H2O2 [5]. Aside from its involvement in secondmessenger signaling, ROS is used as a
microbicidal agent and is crucial for the degradation of the phagocytosed invader [6].
Products of the ROS-induced degradation pathways can be processed and presented
by DCs after phagocytosis, where detection of the non-self-ligands can enhance pre-
sentation of material from the phagosome. This process links the innate and adap-
tive immune responses, as antigen-presenting DCs expressing varying combinations
of cytokines can migrate to the lymph nodes and activate naive T cells [7]. Here, we
will briefly discuss the four PRR families outlining their notable members, main func-
tions, and signaling routes used, and then focus particularly on theDectin-1 cluster of
C-type lectins.
Toll-Like Receptors
The TLRs are considered to be the primary sensing receptors of the innate immune
system and have been implicated in the defence against invading bacteria, fungi and
viruses, amongst others. TLRs are the most extensively studied family of PRRs and,
to date, 13 members have been identified. TLR1–9 are present in both humans and
mice,whereasTLR10andTLR11are expressed inhumansandmice, respectively, both
TLR12 and TLR13 functions and expression profiles remain undefined. TLRs are type
I transmembrane receptors containing a horseshoe-shaped ligand-binding domain
(LBD) and a signaling tail connected by a transmembrane region. The signaling do-
main has structural homology to interleukin-1 receptor (IL-1R) and is subsequently
called the Toll/IL-1 receptor (TIR) domain [8, 9]. Functions of TLRs appear to be di-
rectly correlated with their sub-cellular localisation, for example TLR1, TLR2, TLR4,
TLR5, TLR6 and TLR10 recognise components of bacterial and fungal cell walls and
are therefore largely present on the cell surface, whereas TLR3, TLR7, TLR8 and TLR9
recognise viral andbacterial nucleic acids in intracellular vacuoles [10]. Ligands recog-
nised at the cell surface include lipopolysaccharide (LPS) present on gram-negative
bacteria (by TLR4), as well as gram-positive bacteria component peptidoglycan (by
TLR2). TLR ligands detected within the cell are often virus- or prokaryote-derived nu-
cleic acids, for example TLR3 recognises double-stranded (ds)RNA during viral infec-
tion, whereas TLR9 binds unmethylated CpGDNA fromprokaryotes andDNA viruses
[11, 12].
Signaling through TLRs can induce inflammatory responses such as cytokine and
chemokine expression, which as described previously helps orchestrate innate and
adaptive immunity [11, 13, 14]. TLR signaling often results in activation of NF-κB and
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MAP kinases (MAPKs), both are major components that regulate gene expression.
NF-κB is a transcription factor that is sequestered in the cytoplasm of inactive cells
by proteins such as inhibitor of NF-κB (IκB)α and IκBβ. Upon activation of TLRs, IκB
proteins are phosphorylated by the trimeric complex IκB kinase (IKK), which con-
tains the subunits: IKKα, IKKβ and IKKγ , and is regulated by multiple MAPK kinase
kinases, TAK1 being themost studied. Phosphorylation of IκBproteins labels them for
degradation by the proteasome; this releases NF-κB allowing its translocation into the
nucleus.
A major adaptor upstream of these pathways is MyD88 that controls IκB phospho-
rylation and directly interacts with the TIR domain of the TLR [9]. MyD88, TIRAP,
TRIF, TRAM and SARM are all members of a family of cytoplasmic TIR domain-
containing adaptor proteins that can interact with TLRs. It is these adaptor molecules
that give signaling specificity between TLR members, although MyD88 is able to in-
teract with almost all TLRs (with the exception of TLR3) as well as the other adapter
proteins mentioned [9, 15]. As a result of this, TLR signaling is often viewed as either
a MyD88-dependent or independent process. TLR4 displays the signaling specificity
gained from using multiple TIR domain-containing adaptors in MyD88-independent
pathways; however, it can also activateMyD88-dependent pathways recruiting TIRAP
to induce proinflammatory cytokine expression. In the case of other TLRs, MyD88-
dependent pathways induce proinflammatory cytokine and type I IFN produc-
tion, whereas MyD88-independent pathways involving TLR3 and TLR4, TRIF and
TRAM are used to activate TRIF-dependent pathways leading to expression of type I
IFN [9].
NOD-Like Receptors
NLRs are a family of intracellular PRRs that play important roles in innate immune re-
sponseupon recognition of PAMPswithin the cytoplasm. In addition, they are also be-
lieved to be involved in both pro- and anti-inflammatory responses, and are therefore
keymodulators of the adaptive immune response [16]. So far, 23humanand34murine
NLRs have been discovered, of which both are made up of two subfamilies charac-
terised by different N-terminal domains [14]. The Nod subfamily members contain at
least one caspase-activating and recruiting domain (CARD), whereas the NLRP sub-
family members are defined by the presence of a pyrin domain.These domains allow
the activated receptor to interact with downstream adaptor proteins in a homotypic
CARD–CARD or pyrin–pyrin formation. Aside from these domains, NOD-like recep-
tors have similar structures; they contain a C-terminal domain involved in direct or
indirect binding with PAMPs, as well as a central NOD (alternatively NACHT) domain
involved in oligomerisation with other activated NLRs [17, 18].
Notable members of the Nod subfamily are NOD1 and NOD2, and are among
the most well-studied receptors within the NLR family. They are known to recog-
nise PAMPs found on the surface of bacteria, specifically, NOD1 recognises gram-
negative bacteria peptidoglycan component, meso-diaminopimelic acid, whereas
NOD2 recognises muramyl dipeptide, a component of almost all bacteria, with a few
exceptions [18].NOD1andNOD2contain one and twoCARDs, respectively, andupon
activation by a ligand, they associate with the CARD-containing signaling adapter
RIP2 (alternatively RICK) in a CARD–CARD manner. Active RIP2 is able to remove
inhibition of NF-κB through ubiquitination of IκBγ , facilitated by the E3 ubiquitin
ligases, cIAP1 and cIAP2 [16]. NOD2 has been at the centre of many genome-wide
studies that have revealed 30–40 polymorphisms within the NOD2 sequence associ-
ated with Crohn’s disease, an inflammatory disease that affects the intestinal tract. It
is widely agreed that Crohn’s disease is caused by an increase in the inflammatory
activity against normal gut microflora, and it is currently hypothesised that NOD2
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polymorphisms lead to dysfunctional regulation of inflammation-inducing gut bac-
teria [19]. Unlike NOD1 and NOD2, other members of the Nod family such as NLRC3
and NLRC5 are understudied. Evidence thus far points towards an inhibitory role for
NLRC3, as over-expression reduces MyD88-dependent NF-κB production via the sig-
naling intermediate, TRAF6 [16, 20], whereas NLRC5 has only been recently discov-
ered and has yet to have a determined role within innate immunity [21].
TheNLRP subfamily contains receptorsNLRP1–12,where protein interactionswith
downstream signaling molecules occur through a pyrin domain. The most intriguing
property of certain members of this NLR subfamily is their ability to form a multi-
meric complex known as the inflammasome.NLRP1,NLRP2,NLRP3,NLRC4,NLRC5,
NLRP6 andNLRP7 all have the ability to form an inflammasome after ligand-induced
activation [16].The inflammasome plays an important role in innate immunity, where
the ligand-activated NLR associates with the non-NLR protein ASC along with pro-
caspase-1 and forms the basic unit of the inflammasome. These units can interact in
an assembly analogous to the apoptosome, forming a large multimeric protein com-
plex. From this, the inflammasome cleaves pro-caspase-1 to caspase-1, which in-turn
cleaves TLR-induced pro-IL-1β to IL-1β, an important regulator with the ability to di-
rect local or systemic immune response. As well as IL-1β, the inflammasome also aids
the maturation of IL-18 [14]. Of all inflammasome complexes, the NLRP3 inflamma-
some is the most extensively studied. The NLRP3 inflammasome is known to be di-
rectly and indirectly activatedbymultiplemolecules includingPAMPs foundonbacte-
ria and fungi, endogenous ligands suchaspalmitate andceramide, andnon-biological
environmental crystals such as uric acid, silica and asbestos [14, 22, 23]. There is po-
tential cross-talk between NLRP3 and Spleen tyrosine kinase (Syk)-activating recep-
tors including the C-type lectin-like receptors discussed later, which has important
implications in anti-microbial immunity.
RIG-I-Like Receptors
There are currently three known RLRs: RIG-I, MDA5 and LGP2. These receptors act
as cytoplasmic surveillance proteins that detect viral RNA that is either directly in-
serted into host cells, or released from viral capsules after receptor mediated uptake
and degradation. Structure of RLRs contains a ligand-binding domain for recognition
of dsRNA and, with the exception of LGP2, tandem CARDs at the N-terminus. RIG-I
also contains a repressor domain involved in controlling RIG-I-induced signaling [14,
24]. In terms of ligand binding, RIG-I andMDA5 can recognise RNA viruses; however,
each responddifferently dependingon the species of virus. Paradoxically, LGP2acts as
a positive regulator of bothRIG-I andMDA5, even though it lacks a signal-transducing
domain; however, it is thought that LGP2 acts upstream of these receptors to aid in
recognition of the virus [14, 25].
Signaling throughRLRs leads to recognisableoutcomesof innate immune response
such as NF-κB activation; however, activation pathways differ from those previously
described for other PRRs. In the case of activeRIG-I andMDA5, interferon-β promoter
stimulator-1 (IPS-1, alternatively MAVS) is recruited to the CARD domain and acti-
vates NF-κB via caspase-8, caspase-10, TRADD and FADD [14, 26, 27]. As well as this,
IPS-1 is used as an RLR signaling adaptor to induce and stabilise antiviral response via
two intracellular organelles: mitochondria and peroxisomes. Upon RLR-dependent
activation, IPS-1 can localise to the peroxisome inducing IRF1 activation that results
in a fast-acting response to infection. IPS-1 can also localise to mitochondria where
delayed, yet lasting response to viral infection is induced through activation of IRF3
and type I interferons.These allow the generation of potent responses to viral invasion
[14, 28].
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C-TYPE LECTIN-LIKE RECEPTORS
C-type lectins (CTLs) were originally defined as a family of soluble and transmem-
brane receptors that bound carbohydrates via a carbohydrate recognition domain
(CRD); however, continued research has revealed many structurally homologous do-
mains to the CRD that are not restricted to carbohydrate binding. These domains are
known as C-type lectin-like domains (CTLDs) and can be found on C-type lectin-like
receptors (CTLRs) in varying numbers [29].
Association between the CRD and carbohydrate ligand is facilitated by amino acid
motifs with the ability to bind either mannose- or galactose-based structures. This
interaction involves hydrogen bonding between a single calcium ion and carbonyl
groups present at specific loci in the CRD fold; the calcium ion is also involved in hy-
drogen bonding with the carbohydrate itself.There are four sites where calcium coor-
dination takes place;most important of these is site 2 as it suppliesmost of the binding
affinity for the associated carbohydrate.The type of carbohydrate recognised depends
on the amino acid within which the carbonyl group resides. For example, galac-
tose binding is dependent on the following sequence, Gln-Pro-Asp, whereas man-
nose recognition requires a slightly modified sequence, Glu-Pro-Asn [30, 31]. Despite
loss of these residues, as well as residues important for calcium coordination, cer-
tain CTLDs can recognise a more diverse set of ligands including lipids and proteins
[32]. This group of CTLs are now referred to as CTLRs, and are of particular interest
here.
CTLRs are a family of protein receptors crucial in the recognition of self- and non-
self-ligands. They are so-called due to the presence of one or more CTLDs, and the
1000+ members are organised into 17 groups depending on their phylogeny and do-
main organisation [30]. Ligands bind to the structurally conserved CTLD, which is ob-
served to be a tight-fold constructed from loops stabilised by two disulphide bridges
[31]. Upon ligand binding to this fold, CTLRs canmediate a diverse set of downstream
responses including, for example uptake of microorganisms, regulation of homeosta-
sis such as clearance of apoptotic cells, direction of the adaptive immune response
through cytokine and chemokine expression, and cell–cell adhesion [31, 33].
Receptors of particular significance in this review are the myeloid CTLRs and their
close relatives. These receptors share similar downstream pathways yet their physio-
logical effects are often unrelated. Structural categorisation aside, myeloid CTLRs can
be divided into three main groups depending on their intracellular signaling motifs:
immunoreceptor tyrosine-based activatory motif (ITAM)-bearing, immunoreceptor
tyrosine-based inhibitory motif (ITIM)-bearing and non-immunoreceptor tyrosine-
basedmotif-bearing receptors [31]. CTLRs can signal directly, through integral motifs
in their cytoplasmic tails, or indirectly, through association with adaptor chains.
Most activation receptors associate with ITAM-bearing adaptor chains such as
FcRγ chain, including DC-associated C-type lectin (Dectin)-2 and macrophage-
inducible C-type lectin (Mincle), and DAP12 that can associate with myeloid DAP12-
associating lectin (MDL)-1, for example. The ITAM consensus motif sequence is
[YxxI/Lx(6–12)YxxI/L] and activation occurs when ligand binding causes receptor clus-
tering andphosphorylation of tyrosine residueswithin this ITAMsequence by amem-
ber of the Src family kinases. Many ITAM-associated myeloid receptors utilise the
kinase, Syk, where both SH2 domains of Syk interact with the two phosphotyrosines
within the ITAM to render Syk fully active [34].
Signaling pathways downstream of Syk activation form a large network of which
the ultimate outcome is modulation of innate and adaptive immune responses. Path-
ways include activation of MAPK leading to large-scale changes in transcription of
multiple genes, reorganisation of the actin cytoskeleton through activation of the
International Reviews of Immunology
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Rac and Rho GTPase enzymes and activation of NF-κB through multiple routes. A
well-understood area of CTLR signaling involves phosphoinositide 3-kinase (PI3K)
generating membrane-associated phosphatidylinositol-3,4,5-triphosphate (PIP3) to
activate its most noteworthy downstream enzyme, phospholipase Cγ 2 (PLCγ 2). In-
duction of the inositol triphosphate (IP3) and diacylglycerol (DAG) pathway through
PLCγ 2 activation leads to calcium ion release as a secondmessenger and activation of
various protein kinase C (PKC) isoforms [35]. PKC can activate relatives of the CARD-
containing adaptor, CARD9, which forms a trimeric complex with Bcl-10 and Malt1.
Exactmechanisms linkingPKCdirectly to theCARD9-containingcomplex, rather than
CARD9-relatedproteins, remain amystery; however, it is known thatCARD9-deficient
cells donot activateNF-κBand subsequently lack cytokine and chemokine responses,
suggesting its integral role in activation of NF-κB in a Syk-dependent pathway [36].
Intriguingly, the presence of altered ITAM motifs, termed ITAM-like (alternatively
hemITAM) motifs, appears to activate Syk-dependent pathways even though only a
single tyrosine ispresentwithin thismotif.Whereas thecanonical ITAMmotif contains
a repeat of YxxI/L, an ITAM-likemotif is often described as just a single YxxI/L. At first,
this appears inconsistent with current knowledge of Syk signaling and its requirement
for two individually phosphorylated tyrosines; however, the current hypothesis is that
Syk is able to bridge two receptors that contain a single phosphotyrosine [4].
Downstream signaling from ITAM/ITAM-like motifs are not restricted to the
CARD9-containing complex; in the case of Dectin-1 (an ITAM-like-containing recep-
tor) and Dectin-2 (an FcRγ -associated receptor), the CARD9 pathway is one of many
transduction pathways initiated by the ITAM motif. For instance, NFAT activation
throughDectin-1 results in characteristic cytokinepatterns such as increased IL-2 and
IL-10 in DCs. ERK and JNKMAPK pathways are also associated with NFAT activation,
as both require the active PLCγ 2 pathway for continuous transduction. In addition,
Dectin-1 and Dectin-2 are also both associated with production of ROS (discussed
earlier), which has implications in the secretion of IL-1β by aiding activation of the
NLRP3 inflammasome [22, 31].
As discussed, ITAM signaling is very versatile and these pathways can lead to phys-
iological effects such as phagocytosis, cell proliferation,migration, differentiation and
adhesion. However, activation of these responses is only half of the story, controlling
these mechanisms is also a vital process. Receptors containing ITIM motifs are often
implicated in negative regulation of pathways activate through ITAMs.
The ITIMsequence is describedas [I/V/L/SxYxxI/L/V],where the central tyrosine is
phosphorylated by the Src family kinases. However, rather than recruiting Syk, ITIM-
bearing receptors recruit tyrosine phosphatases to negatively regulate the activity of
signalingpathways [4]. Inmany cases, ITIM-containingCTLRs associatewith the SH2-
domain-containing protein tyrosine phosphatase (SHP)-1 and SHP-2, which are able
todirectly affect the signaling capabilities of JAK/STATand ITAMpathways. SHP-1 and
SHP-2 are also able to regulate TLR pathways reducing NF-κB activity; however, these
interactions are not yet fully understood, and could potentially involve reduction of
synergistic collaboration between TLRs and other PRRs [31]. As well as SHP-1 and
SHP-2, association can occur between an ITIMmotif and SH2 domain-containing in-
ositol phosphatases (SHIP)-1 and SHIP-2, inhibiting signals that are initiated by PI3K
through dephosphorylation [37].
There are also CLRs and CTLRs that signal throughmotifs that do not fit the recog-
nised ITAM, ITAM-like or ITIM sequences. Signaling pathways involving such mo-
tifs are unknown for most; however, for a few receptors, some pathways have been
somewhat illuminated. One such elucidated receptor is DC-SIGN; it contains two
of the most notable non-immunoreceptor tyrosine-based motifs, the di-leucine mo-
tif and the tri-acidic motif that are thought to be involved in modulation of other
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receptor pathways including the TLR signaling [38]. Specifically, these motifs appear
to be able to modulate Raf-1 activity, a MAPK kinase kinase, leading to the phospho-
rylation and subsequent recruitment of histone acetyltransferases (HATs) to p65, a
subunit of NF-κB. Recruitment of HATs to p65 results in its acetylation and subse-
quently revealing promoters for IL-6, IL-10 and IL-12, increasing their transcription.
DC-SIGN is not the only receptor to activate Raf-1 in a tyrosine-independent manner
but Dectin-1 has also been implicated in this although the mechanisms involved are
unclear [31, 36]. It is important to note that these responses occur alongside TLRpath-
ways after TLR-specific activation, as a form of signal modification [39, 40]. It is also
apparent that these motifs may act as a form of pathogen differentiation, for example
formation of a multiprotein complex known as the signalosome in DC-SIGN signal-
ing is highly dependent on the activating ligand present; specifically mannose-based
ligands recognisable by DC-SIGN retain the signalosome form, allowing activation of
downstream effectors, whereas recognition of fucose-based ligands causes dissocia-
tion of this complex [39]. Other receptors utilising unusual pathways include murine
SIGNR1 that signals through non-immunoreceptor tyrosine-based motifs and shows
collaboration with TLRs and Dectin-1. Evidence for this is that ROS production in re-
sponse to Candida albicans through Dectin-1 is enhanced by SIGNR1 [41].
The Dectin-1 cluster is one of many receptor clusters that reside within the natural
killer gene complex (NKC) whose functions spanmany areas of immunity and home-
ostasis. Many of the signalingmotifs discussed for CTLRs above can be found in cyto-
plasmic tails of Dectin-1 cluster receptors and these CTLR have a broad range of func-
tions. In the remainder of this review, we will discuss the receptors within this cluster
in detail, including their ligands, signaling pathways, synergistic collaborations and
their roles in immunity and homeostasis.
THE DECTIN-1 CLUSTER
The Dectin-1 cluster form part of the group V C-type lectin-like receptors that have
a single CTLD connected to an intracellular signaling domain via a stalk and trans-
membrane region and were thought to have arisen through gene duplication. These
receptors lacking carbohydrate-binding motifs and largely recognise ligands in a
calcium-independentmanner. Receptors forming theDectin-1 cluster include CLEC-
1, CLEC-2, Dectin-1, CLEC-9A, Myeloid Inhibitory C-type-like Lectin (MICL/CLEC-
12A), Macrophage Antigen H (MAH/CLEC-12B) and Lectin-like Oxidised LDL
receptor-1 (LOX-1) (Figure 1). Each one has the ability to regulate its owndownstream
signaling, analogous to that of the TLRs, due to the presence of one ormore functional
motifs within their intracellular tails. These receptors can be found primarily, but not
entirely, on myeloid cells such as DCs, macrophages and neutrophils, where they
can orchestrate all of the functions described for CTLRs earlier. Functions of recep-
tors within the Dectin-1 cluster are predetermined, in that signaling motif(s) present
within their intracellular domain dictate how they respond to extracellular stimuli,
these motifs are ITAM-like, ITIM and tri-acidic sequences [31, 33, 42].
Dectin-1 (CLEC-7A)
Dectin-1 is a CTLR that was discovered to bind β-1,3-glucans and mycobacteria as
well as an endogenous ligand present on T-cells [43, 44]. Since then, Dectin-1 has be-
come one of the most intensively studied CTLRs with many of its characteristics well
defined, and it has becoming amodel receptor for signalingCTLRs. Although its name
originates from “dendritic-cell-associated C-type lectin 1”, Dectin-1 is not exclusively
expressed on DCs and can be found on other cell types including macrophages, neu-
trophils andmonocytes.
International Reviews of Immunology
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 A
be
rd
ee
n]
 at
 06
:06
 11
 M
arc
h 2
01
6 
Signaling by C-Type Lectin-Like Receptors 
FIGURE 1. Schematic representation of the family of group V type II CTLRs known as the
Dectin-1 cluster. A:Theactivatory receptors Dectin-1, CLEC-2 and CLEC-9A containing ITAM-like
and, with the exception of CLEC-9A, tri-acidic motifs important for downstream signaling. B:The
inhibitory receptors MICL and MAH containing canonical ITIM motifs. C: Receptors containing
novel motifs including C-type lectin-like scavenger receptor LOX-1, containing a DDL motif and
CLEC-1 containing an uncharacterised tyrosine-basedmotif as well as a tri-acidic motif.
Like other group V type II transmembrane receptors, Dectin-1 contains a single ex-
tracellular CTLD, which is involved in calcium-independent ligand interactions, con-
nected to a single-pass transmembrane domain by a stalk region. Attached to the cy-
toplasmic end of the transmembrane region lays a small intracellular tail, where the
Dectin-1 ITAM-like [YxxL] and tri-acidic [DED] motifs reside [33]. Both murine and
humanDectin-1homologueshavemultiple splice variants althougheachhas twoma-
jor isoforms. The major isoforms differ in either the gain or lack of the stalk, isoforms
A and B, respectively, and are the only receptors capable of binding β-glucans [4].
Dectin-1 is alsoN-glycosylated, affecting its expression and function [33].
Through the recognition of β-glucans, Dectin-1 binds several fungal species such
as Aspergillus, Candida, Coccidioides, Penicillium, Pneumocystis and Saccharomyces
and because of this, focus on the immunological role forDectin-1 has been directed at
fungal immunity. Upon binding of β-glucans, Dectin-1 can induce a vast array of cel-
lular effects including actin-mediated phagocytosis, activation of the respiratory burst
through production of ROS, endocytosis, DCmaturation and changes in cytokine and
chemokine expression patterns such as TNF-α, IL-1α, IL-1β, IL-6, CXCL2, CCL3 and
GM-CSF [5, 33]. Although recent data suggest that Dectin-1 does not play a role in
controlling C. albicans colonisation of the GI tract, Dectin-1 does play a major role in
systemic candidiasis and other mucosal infections. Dectin-1 can direct effective anti-
fungalmechanisms throughT-helper cell (TH)-1 and17 responses,whicharedefective
in human patients with homozygous non-functional Dectin-1 [45, 46]. In addition to
fungal ligands, Dectin-1 can also recognise an unidentified ligand on mycobacteria,
which leads to the production of IL-12 [31].
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FIGURE 2. Signaling network of Dectin-1. Multiple pathways downstream of Dectin-1 rely
on Syk. This can lead to PLCγ 2/Ca2+ signaling leading to PKCδ activation that controls cal-
cineurin/NFAT and ROS/NLRP3 inflammasome, and the phosphorylation of CARD9-Bcl10-Malt1.
TheCARD9 complex is able to activate all NF-κB subunits including c-Rel by removing its inhibitor,
IκB, through activation of the IKK complex. Syk can also activate IKK complex through the non-
canonical NIK pathway, leading to the activation of NF-κB subunits RelB and p52. This pathway
can be inhibited the Raf-1-mediated pathway involving p65. Phosphorylated and acetylated p65
can interact with RelB, sequestering it away from an active NF-κB complex. Resultant activation of
NFATandNF-κB results inmodificationof gene transcription including cytokines and chemokines.
Dashed arrows represent a pathway that has yet to be fully defined.
Dectin-1 signaling downstreamof ligandbinding involves both Syk-dependent and
Syk-independent signaling cascades (Figure 2), along with pathways from collaborat-
ing receptors such as those of TLRs. Within these networks, pathways leading to the
Syk-dependent activation of NF-κB can be categorised into both canonical and non-
canonical routes.The canonical pathway is as described for the TLRs, where the phos-
phorylation of IκB complex by IKK releases NF-κB allowing its translocation into the
nucleuswhere it can regulate gene transcription.However, unlike TLRs,Dectin-1 acti-
vates this IKK pathway through Syk association with an ITAM-like motif, where active
Syk can phosphorylate PLCγ 2, allowing subsequent activation of the CARD9-Bcl10-
Malt1 complex via PKCδ.
PLCγ 2 is known to indirectly interact with a close relative of CARD9 called
CARMA1 in other receptor pathways. This interaction is based on the hydrolytic ac-
tivity of PLCγ 2 on the phosphorylated membrane phospholipid PIP3 and results in
membrane-anchoredDAG and soluble IP3, both of which aid in activation of PKC iso-
forms. Active PKC can stimulate CARMA1, allowing formation of a complex with Bcl-
10 andMalt1,much like theCARD9complexpresent inDectin-1 signaling [47]. Recent
evidence has shown that the CARD9 activation pathway is analogous to the CARMA1
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pathway, as CARD9 phosphorylation is heavily reliant upon the PKCδ isoform in re-
sponse toDectin-1 stimulation. Indeed, PKCδ knockoutDCs aredefective inDectin-1-
mediated responses.TheCARD9-Bcl10-Malt1 complex inDectin-1 signaling is known
to activate subunits of NF-κB through the IKK complex as described for the TLRs, and
of particularnote isMalt1-dependent activationof the subunit c-Rel,which is required
for TH17-inducing cytokines IL-1β, and IL-23p19, and immunity against Candida in-
fection [32, 48, 49].
Aside from the canonical NF-κB activation pathway, Dectin-1 alsomediates a non-
canonical pathway utilisingNF-κB-inducing kinase (NIK) through Syk activation. NIK
can activate IKKα leading to production of p52 from its precursor, p100. Dimers of p52
and RelB can translocate into the nucleus and induce transcription [32]. In addition,
Dectin-1 activates a Syk-independent pathway through its tri-acidic motif [DED] in-
volving Raf-1 activation by Ras, the end result of which is a merging of non-canonical
NF-κB and Raf-1 pathways. Raf-1-induced phosphorylation of p65 results in the for-
mation of a p65-RelB dimer that sequesters active RelB, this prevents RelB binding to
DNA, and favours Raf-1-dependent IL-12p70 production required for TH1 differentia-
tion, as well as IL-1β, IL-23, IL-6 that are involved in TH17-polarising cytokines [4, 31,
32, 49].The DEDmotif is also required for efficient phagocytosis by this receptor [50].
This network of Dectin-1-induced pathways also involves the activation of the tran-
scription factor, nuclear factor of activatedTcells (NFAT).Dectin-1 signals through the
classic calcineurin/NFAT pathway through Syk activation of PLCγ leading to soluble
IP3 as described earlier. IP3 is able to bind endoplasmic Ca2+ channels, resulting in
an influx of Ca2+ into the cytoplasm. This increase in calcium concentration induces
calcineurin activation and consequently, dephosphorylation of NFAT and transloca-
tion into the nucleus. NFATs role within the innate immune system, in particular DC
cytokine expression, is potent expression of IL-2 and IL-10, regulating development in
lymphocytes and Tregs, as well as differentiation and survival of the latter [51].
It is now widely accepted that receptors collaborate and that this is an important
component for effectively controlling infection. Indeed Dectin-1 can collaborate with
many MyD88-coupled TLRs including TLR2, TLR4, TLR5, TLR7 and TLR9 [4]. Cou-
pling between Dectin-1 and TLR2 has been shown to be important in phagocytosis
as well as MAPK activity in the control of Candida infections, where cooperative sig-
naling is required to trigger effective cytokine production and drive TH17 responses
[52]. Furthermore, Dectin-1 has been shown to collaborate with SIGNR1 inducing
TNF [53], TLRs including TLR2, TLR4, TLR5, TLR7 and TLR9 through MyD88 and
Syk-dependent pathways [54] as well as the tetraspanin CD63, during phagocytosis
of Saccharomyces cerevisiae in DCs [55]. Dectin-1 is also able to activate complement
receptor 3 (CR3, alternatively Mac-1) to enhance fungal recognition and neutrophil
response through collaborative function. This involves the activation of downstream
Vav1 and Vav3 as well as PLCγ by Dectin-1 to activate CR3, resulting in combined
signaling to enhance phagocytosis and ROS production of neutrophils at the site of
infection [56].
CLEC-9A
CLEC-9A is structurally similar to other group V type II transmembrane receptors
described, and contains an ITAM-like motif [YxxL] within its intracellular tail. There
are multiple splice variants of murine CLEC-9A; the 6-exon variant is expressed as a
non-glycosylated monomer, whereas the 7-exon variant is expressed as a dimer. This
variant was shown to be expressed on plasmacytoid DCs and, interestingly, CD8α+
DCs that are highly efficient at antigen cross-presentation [57, 58]. Human CLEC-9A
is predominantly expressed as glycosylated dimers on BDCA3+ DCs that are known
to be the equivalent to murine CD8α+ DCs due to similarities in expressed surface
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markers [59].Theextracellular region of CLEC-9A contains aCa2+-independentCTLD
that binds a proteinaceous ligand known to be ubiquitous to all cell types and exposed
during necrotic cell death. Recent developments have uncovered this endogenous
ligand to be F-actin; a major, highly conserved component of the cytoskeleton from
yeast to man [60, 61]. CLEC-9A has been shown to help mediate cross-presentation
of necrotic cell-associated material for priming of cytotoxic T cells, acting as a link
between innate recognition and T-cell responses [61, 62]. Interestingly, recent find-
ings have suggested that CLEC-9A-dependent cross-presentation involves endocy-
tosed material that is presented via the internal cross-presentation pathway, rather
than the external pathway [63]. However, unlike Dectin-1, binding of F-actin to CLEC-
9A had no appreciable effect on cellular cytokine responses suggesting that CLEC-9A
is not an activation receptor and that cross-presentation is its primary function [61,
64]. Additional evidence for its non-activation function was shown through antibody
cross-linking of CLEC-9A, which also had no effect onDC activation; likewise, Dectin-
1/CLEC-9A chimeric receptors stimulated with β-glucans showed no signs of DC ac-
tivation [31, 57, 58]. On the other hand, mutation of an isoleucine to a glycine directly
upstream of the ITAM-like motif within the Dectin-1/CLEC-9A chimera results in in-
creased cytokine production, suggesting that CLEC-9A can activate myeloid cells, but
that this function is restricted by the presence of an isoleucine within the cytoplasmic
tail [63].
Linking CLEC-9A functions to signaling networks is in its infancy; however, what is
known is that cross-presentation is dependent on Syk recruitment to the phospho-
rylated ITAM-like motif (Figure 3). Investigations into the ITAM-like motif revealed
that antibody cross-linking to the CTLD induced tyrosine phosphorylation and sub-
sequent Syk recruitment in vitro, this was also observed when CLEC-9A was exposed
to necrotic cells in vitro. Continued research on the role of CLEC-9 as ITAM-likemotif
used tyrosine mutant receptors to show that the tyrosine was required for functional
cross-presentation. These mutants showed marked reduction in cross-presentation
[65].
CLEC-2 (CLEC-1B)
CLEC-2was discovered alongwith CLEC-1 in a bioinformatic screen forNK receptors.
Expression of CLEC-2 was determined by RT-PCR, where mRNA was found in bone
marrow cells, DCs, monocytes, granulocytes and someNK cell populations; however,
most studies have focussed on the role of CLEC-2 on platelets, where the receptor is
expressed at the cell surface [4].MurineCLEC-2 has three splice variants, two ofwhich
are retained within the cytoplasm due to the lack of a transmembrane region. The
sequence analysis revealed an ITAM-like motif [YxxL] present in the cytoplasmic tail
similar to thosewithinDectin-1 andCLEC-9A andmultiple studies have shown this to
play an important role in platelet signaling in response to endogenous and exogenous
ligands [66, 67].
Known ligands of CLEC-2 include the endogenous protein podoplanin, a trans-
membrane sialoglycoprotein found inmultiple cell types such as lymphatic endothe-
lial cells, type I lung alveolar cells and some cancer cells. Podoplanin-deficient and
CLEC-2-deficient mice have defects in vascular and lymphatic connections, leading
to blood in the lymph [31, 68]. HIV-1 is thought to be recognised by CLEC-2; however,
it is likely that recognition involves a host protein that is incorporated during HIV-1
budding, as binding occurred in the absence of envelop protein. In the case of CLEC-
2 recognition, this host protein has been hypothesised to be podoplanin as evidence
suggests thatHIV-1 can infect renal cells, a commonsite for podoplanin expression [4].
CLEC-2 also binds the exogenous ligand rhodocytin, a multimeric protein found
in snake venom that has been shown to lead to platelet activation, aggregation and
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FIGURE 3. ITAM-like-bearing CTLRs within the Dectin-1 cluster. As well as Dectin-1, there are
two additional receptors that contain ITAM-like motifs. These receptors share Syk as a primary
downstream signaling kinase; however, the lack of a tri-acidic in CLEC-9A and the presence of
an isoleucine prevent the endocytic and activation functions of this receptor. CLEC-2 utilises its
tri-acidic motif to complement activation through Syk resulting in adhesion and clot formation in
platelets. Dashed arrows represent a pathway that has yet to be fully defined.
subsequent coagulation of the blood [67, 69]. Its tetrameric structure is thought to aid
in CLEC-2 clustering at the cells surface resulting in amplification of downstream sig-
naling [4]. Binding of these two ligands may occur through different mechanisms as
rhodocytin interacts directly with CLEC-2 [70], whereas glycosylation of podoplanin
is involved in CLEC-2 binding [71].
The functions of CLEC-2 have become more apparent in recent years, for example
platelet activation is nowknown tobean important factor in tumourmetastasis,which
may be triggered by up-regulation of podoplanin at the cell surface [72]. In addition to
this, CLEC-2 has also been implicated in arteriolar rate of flow in mice [73] as well as
phagocytic roles in neutrophils, suggesting a potential role within innate immunity
[74]. As with other CTLRs in the Dectin-1 cluster, signaling from CLEC-2 requires Syk
association (Figure 3), however, unlike knowledge currently described; this ITAM-like
motif has differentmodes of activation compared to the canonical ITAMmotif [68, 69,
75]. Because of this, CLEC-2 has become somewhat of a model for ITAM-like signal-
ing,withmultiple features of thismotif revealed in recent studies.Of particular interest
here is the use of a tri-acidicmotif [DED] present upstreamof the ITAM-likemotif that
is able to facilitate tyrosine-basedsignalingandpartake in ITAM-like-independent sig-
naling [68].
Mutational analysis of the CLEC-2 tri-acidic cluster showed that phosphorylation
of the ITAM-likemotif wasmarkedly reduced and resulted in a complete loss of CLEC-
2 signaling, suggesting that the tri-acidic motif is required for phosphorylation the
ITAM-like motif. Another interesting observation is that in the presence of a highly
selective Syk inhibitor, CLEC-2 ITAM-like phosphorylation was completely blocked,
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whereas phosphorylation of ITAM-containing adaptors such as FcRγ was not per-
turbed. In addition to this, phosphorylation of Syk was shown to precede phosphory-
lation of the ITAM-like motif in an Src-dependent manner. This suggests that CLEC-2
ITAM-like phosphorylation is dependent upon Syk, quite opposite to previous mod-
els, where Src family kinases phosphorylate the ITAM-like motif allowing Syk binding
[68, 75].
Functional studies into thephagocyticpotential ofmyeloid-expressedCLEC-2were
done using chimeric receptors containing the extracellular and transmembrane do-
main of Dectin-1 fused to the signaling tail of CLEC-2. It was determined that CLEC-2
can induce phagocytosis, NFAT activation and TNFproduction; however, the receptor
is unable to activate the respiratory burst. Although the mechanisms behind the Syk
involvement inCLEC-2-mediatedphagocytosis are still not fullyunderstood, it is likely
that the tri-acidic cluster upstreamof the tyrosine is critical for this, as it is forDectin-1.
Withmultiple characteristics similar to Dectin-1, CLEC-2may be able to function as a
PRR inaddition to itswell-knownhomeostatic role inplatelet activation [74].However,
exogenous ligands (other than rhodocytin) are currently unknown.
Recent evidence suggests that phosphorylation of CLEC-2 is dependent on multi-
ple factors; these include association with lipid rafts, actin polymerisation and Rac-1
activation [76]. CLEC-2 was found within lipid rafts, presumably bringing it into close
proximity with important downstream signaling components.This process was deter-
mined to be actin-independent; however, in the presence of an actin polymerisation
inhibitor, CLEC-2 phosphorylationwas reduced, suggesting that actinmay have a role
in Src function or recruitment [73]. Furthermore, an increase in CLEC-2 ITAM-like ty-
rosine phosphorylation in the presence of the platelet secondary mediators ADP and
Thromboxin A2 (TxA2) upstream of Rac-1 was observed. This increase in activation is
able to bypass the need for actin polymerisation; therefore, Rac-1 activation may re-
sults in a feedback loop affecting the Src family kinases.
CLEC-2 is also thought to activate PLCγ 2 via Syk-phosphorylation, along with ad-
ditional support from active Rac-1 [77]. PLCγ 2, as discussed earlier, is a lipase that
when activated in platelets leads to platelet-specific responses such as adhesion and
clot formation throughCa2+ influx into the cytoplasm.Although the interplaybetween
PLCγ 2 andRac-1 is not fully understoodwithinCLEC-2 signaling, Rac-1 could be sup-
porting PLCγ 2 signaling through production of PLCγ 2 substrates as well as directly
interacting with it, as observed in other receptor pathways [73].
Evidence of receptor co-stimulation also exists with CLEC-2 pathways, where ad-
dition of anti-CLEC-2 monoclonal (mAb) along with LPS can potentiate the effects of
TLR function, further suggesting a role for CLEC-2 in inflammatory responses. This is
supported by data that suggest CLEC-2 expression increases onmyeloid cells after ex-
posure to LPS, which also increases IL-10 production possibly through the Syk/NFAT
activation pathway. A noteworthy point is that CLEC-2 activation was achieved using
antibody crosslinking, and true ligands of this receptor may illicit different responses
[78].
MICL (CLEC-12A)
HumanMICL (alternatively DCAL-2, CLL-1 and KLRL-1) was discovered in a genome
search for sequences homologous to theCRDofDC-SIGNandDCIR.Unlike the previ-
ously discussedDectin-1 cluster receptors,MICL is an inhibitory CTLR, containing an
ITIM motif [human: VxYxxL, murine: IxYxxL] within its intracellular tail. There are at
least three isoforms of human (h)MICL: α, β and γ , where β-isoform lacks the trans-
membrane domain and γ -isoforms lacks the CTLD. The receptor also contains cys-
teine residues that are often associated with dimerisation; however, hMICL is found
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as a monomer and is heavy glycosylated. This is unlike its murine counterpart that is
expressed as a dimer and lacks heavy glycosylation.
MICL is principally expressed on myeloid cells including DCs and macrophages,
and is down-regulated during stimulation with TLR ligands, cell migration into pe-
ripheral tissues and sites of inflammation; a classic response seen in many inhibitory
receptors. Specific ligands for MICL are currently undefined; however, soluble MICL
was used to probe for potential ligands in many different tissues revealing binding in
bonemarrow, thymus, heart, spleenandkidney.Thiswidespread recognition suggests
that MICL may play a role in regulation of homeostasis [33, 79, 80]. MICL is also ex-
pressed on acute myeloid leukaemia (AML) cells, where it is used as a marker and
having a potential role in AML therapeutics. Only 30–40% of patients affected by AML
survive due to the tolerance this cell type has to chemotherapy upon relapse. Recent
progress using MICL as a therapeutic target involved the development of cytotoxic
anti-MICLmAbs to target AML-derived cells.These mAbs showed strong cytotoxicity
against 94% of AML-derived cells, demonstrating a promising approach to the treat-
ment of AML usingMICL as a target [81, 82].
Of particular interest here is MICLs ability to regulate the activation responses
downstream of PRRs including TLRs and CTLRs, as this would have direct effects on
cellular response during pathogenic invasion. As described earlier for ITIMs,MICL re-
cruits SHP-1 and SHP-2 via their SH2 domains to the phosphorylated tyrosine within
the ITIM, and this pathway is thought tomediate the inhibitory function of this recep-
tor (Figure 4). MICL’s inhibitory function has been directly demonstrated using a fu-
sion of the Dectin-1 CTLD with the signaling tail of MICL. When this MICL/Dectin-1
chimeric receptor was co-expressed with full length Dectin-1, MICL signaling could
successfully inhibit zymosan-induced stimulation of Dectin-1 [80]. During another
study, the effects of MICL on cytokine and chemokine production were investigated;
MICL was shown to suppress zymosan and LPS-induced IL-12p40 and IL-12p70 as
well as LPS-induced TNF expression [83]. In addition to this, anti-MICL antibody
cross-linking suppressed TLR-induced IFN-γ production in mature DCs; however, in
DCs activated through CD40, IFN-γ production was activated, suggesting differential
roles depending on the method of DC activation. MICL is also described to have an
inhibitory role in NK cell cytotoxicity, where blocking of potential MICL ligands in-
creasedNKtoxicity [84].Antibodycross-linkingofMICL is alsoable to stimulateMAPK
pathways in immature DCs (iDCs) and although these DCs do not mature, MICL was
able to induce cytokine and chemokine expression aswell as antibody internalisation.
This suggests that in certain circumstancesMICLmay also have an activation role [83],
which has been described for other inhibitory receptors [79].
MAH (CLEC-12B)
MAHwasdetected throughcomputational analysis andhas considerablehomology to
the activation receptorNKG2D. It has two isoforms,which are expresseddifferentially,
one is expressed widely amongst cell types excluding the brain, whereas the other is
expressed in tissues such as the lungs, mammary gland and ovaries; however, the lat-
ter is predicted to be non-functional due to the lack of a section of its CTLD. More
recently, the presence of MAH mRNA was shown in DCs, monocytic cells and lym-
phocytes [85]. Sequence data show that MAH contains an ITIMmotif [VxYxxL] within
its signaling tail, suggesting that it may well be an inhibitory partner of NKG2D; how-
ever, as they share no known ligands and their expression profiles on T cells and NK
cells are different, this is unlikely [86].
Only a few aspects of the human MAH signaling pathway are known (Figure 4); it
can associate with the tyrosine phosphatases SHP-1 and SHP-2 that can reduce the ef-
fects of kinases within ITAM-mediated pathways. AlthoughMAH is most likely not an
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FIGURE 4. ITIM-bearing CTLRs within the Dectin-1 cluster. The ITIM motif within MICL and
MAH is known to interact with SHP-1 and SHP-2; however, pathways downstream of these phos-
phatases are only partially known. MICL is known to inhibit cytokine transcription instigated by
other receptors as a method of control. On the other hand, there is evidence to suggest that MICL
induces activatory pathways through MAPK, which is somewhat contradictory to the known func-
tions of its motif. Downstream signaling of MAH is largely unknown. Dashed arrows represent a
pathway that has yet to be fully defined.
inhibitory partner ofNKG2D, it is able to inhibit somepathways induced byNKG2Das
well as otherNK receptors including 2B4.Nevertheless, this inhibitionwasnot enough
to prevent NK cell activation [86]. Knowledge of MAH function and physiological role
will be greatly increased upon discovery of a ligand.
CLEC-1 (CLEC-1A)
CLEC-1 is almost completely uncharacterised and although there is evidence to sug-
gest a few conserved residues between the mouse and humans, none of these have
been proven to aid in downstream signaling to date. Bioinformatic predictions into
the structure of CLEC-1 describe it as being a group V type II transmembrane recep-
tor with some potentially noteworthy residues present within its intracellular tail [66,
87]. Literature also describes two conserved cysteine residues within the stalk region
that are hypothesised to allow CLEC-1 to form homodimers facilitated by disulphide
bridges [88]. However, functional work on CLEC-1 is restricted due to the lack of a
known ligand.Notable residueswithin the intracellular tail are a tyrosine that presents
International Reviews of Immunology
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 A
be
rd
ee
n]
 at
 06
:06
 11
 M
arc
h 2
01
6 
Signaling by C-Type Lectin-Like Receptors 
FIGURE 5. CTLRs within the Dectin-1 cluster that contain novel signaling motifs.Many com-
ponents downstream of LOX-1s novel DDL motif have been determined, although exact mecha-
nisms are not entirely identified. Interestingly, LOX-1 has the ability to up-regulate transcription of
other receptors including itself; a mechanism that has been shown to aid in plaque formation dur-
ing atherosclerosis. Downstream signaling of CLEC-1 is largely unknown; however, it does contain
a tri-acidic motif that may have signaling potential due to similar signaling sequences in Dectin-1
and CLEC-2. Dashed arrows represent a pathway that has yet to be fully defined, and the grey arrow
represents potential pathways based on other related receptor functions.
itself in an undefined signaling sequence [YSST] as well as the presence of a tri-acidic
cluster [DDD] that could potentially mediate signaling in ways analogous to tyrosine-
independent signaling instigated byDectin-1 [66, 87] (Figure 5). However there are no
data to support either of these being a functional motif.
What is known of CLEC-1 is that it is expressed on myeloid and endothelial cells,
and over-expressed in rat allograft tolerance studies, where its expression is up-
regulated by IL-10 and TGFβ. Observations of function showed that alloantigen-
induced CD4+ CD25+ T cells at the site of allograft increased expression of CLEC-1 in
tolerated allograft endothelial cells. Interestingly, this up-regulationwas not observed
in rejected allografts, suggesting that CLEC-1 has a potentially protective role in trans-
plantation. In addition to this, increased expression of CLEC-1 in tolerated allografts
directly correlated with an increase in Foxp3 and a decrease in IL-17 expression, sug-
gesting that CLEC-1 may regulate T-cell responses [89].
LOX-1 (CLEC-8A)
LOX-1 was the first of the Dectin-1 cluster receptors to be discovered and is often con-
sidered a scavenger receptor, because of its ligands (see below). It is expressed in low
levels primarily on endothelial cells as well as iDCs, macrophages, monocytes and B
cells and induces signalingpathwayswithin these cell typesusinganovelAsp-Asp-Leu
(DDL)motif. Glycosylation of LOX-1 and its dimerisation at the cell surface is thought
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to aid ligand recognition, of which oxidised low-density lipoproteins (OxLDL) is the
mostwell known.However, LOX-1 recognition is not restricted toOxLDL, it can recog-
nise other oxidised lipid structures as well as HSP70 exposed in apoptotic cells, phos-
pholipids, gram-positive and gram-negative bacteria, and activated platelets. Recog-
nition of these ligands can result in a large variety of downstream responses such as
antigen cross-presentation, endocytosis, phagocytosis, cytokine and NF-κB produc-
tion, ROS production, cell adhesion and apoptosis, but themost noteworthy of LOX-1
functions is its role within vascular diseases including hypertension, cardiovascular
disease and atherosclerosis [90, 91].
LOX-1’s role in vascular diseases has been intensively studied as it is often up-
regulated in response to pro-atherogenic factors, leading to progression of atheroscle-
rosis. Atherosclerosis is the formation of vascular plaques as a result of damage to the
lining of the blood vessels often caused by oxidative stress from multiple risk factors
including high blood pressure, smoking and diabetes mellitus. At the site of damage,
LDL-cholesterol can enter into the sub-endothelial space becoming oxidised in the
process, forming OxLDL. Being the primary cause of endothelial damage, OxLDL is
ingested by scavenger receptors such as LOX-1, SR-A1 and SR-A2 present on the sur-
face of macrophages, resulting in their conversion into foam cells and formation of a
fibrous capsule to surround the damaged area, known as an atheroma [92]. Multiple
atheromas can cause blood vessel rigidity, increasing blood pressure and, therefore,
causing further vessel damage in a positive feedback loop, leading to acute coronary
syndrome (ACS). ACS is a major cause of mortality in developed countries; however,
methods of detecting the coronary lesions typical of ACS do not exist. An important
part of LOX-1 involvement in ACS is when it is cleaved to form a soluble receptor that
circulates in the blood, a function that could be utilised as a biomarker for ACS. Unlike
the biomarker used for cardiac muscle damage (troponin T), soluble LOX-1 concen-
trations in the blood peak earlier, therefore allowing the onset of ACS to be detected
before plaques become damaged or rupture [93–95].
Outside of vascular homeostasis, macrophages expressing LOX-1 have been re-
cently shown to bind the GroEL homologue present on the surface of Escherichia coli.
Not only were the macrophages able to bind E. coli, they were able to internalise the
bacteria and increase LOX-1 expression upon binding. Interestingly, rather than aid-
ing the removal ofE. coli from thehost, itmade thehostmore susceptible toperitonitis.
Pre-treatment of thehostwith ananti-LOX-1 antibody reduced susceptibility, suggest-
ing that LOX-1 aids in the invasiveness of E. coli during infection [96].
Multiple signaling pathways have been associatedwith LOX-1 upon activationwith
OxLDL;however, they are yet tobe fully defined (Figure 5).There is evidence to suggest
that LOX-1 signaling involves nuclear translocation of NF-κB via activation of NADPH
oxidase [97]. NADPH oxidase induces the production of ROS, which is a second mes-
senger that is able to activate MAPK and PI3K pathways, leading to NF-κB activation.
In addition, LOX-1 activation is thought toup-regulateCD40andCD40 ligand levels as
well asup-regulationofmonocyte chemoattractantprotein-1andadhesionmolecules
that aid inmacrophagemigration and infiltration of the exposed endothelial layer [97,
98]. OxLDL-mediated activation of LOX-1 also results in apoptosis through activation
of pro-apoptotic factors such as caspase-3 and caspase-9 as well as down-regulation
of anti-apoptotic factors including Bcl-2 and cIAP1 [99].
CONCLUSION
Receptors of theDectin-1 cluster can be separated into two groups depending on their
signaling functions: activation and inhibitory receptors. Although some of these re-
ceptors are largely uncharacterised, new and exciting functions are constantly being
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discovered, and not just in the recognition of pathogens but in the control of home-
ostasis and disease. Equally excitingly are the new insights into the pathways and
mechanisms of intracellular signaling utilised by these receptors. Given the increas-
ingly clear evidence of the importance of these receptors in immunity and homeosta-
sis, gaining a better understanding of their functions and underlying mechanisms is
essential if we are ever to utilise this knowledge for the development of novel im-
munotherapeutic approaches.
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ABBREVIATIONS
ACS acute coronary syndrome
AML acute myeloid leukaemia
ASC apoptosis-associated speck-like protein containing a CARD
Bcl B-cell lymphoma
BDCA thrombomodulin/CD141
CARD caspase-activating and recruiting domain
CARMA CARD recruited membrane-associated protein
CCL chemokine ligand
CD cluster of differentiation
cIAP cellular inhibitor of apoptosis
CLEC C-type lectin-like receptor
CR complement receptor
CRD carbohydrate recognition domain
CTL C-type lectin
CTLD C-type lectin-like domain
CTLR C-type lectin-like receptor
CXCL CXC ligand
DAG diacylglycerol
DAP DNAX-activation protein
DC dendritic cell
DCIR dendritic cell immunoreceptor
DC-SIGN dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin
Dectin dendritic cell-associated C-type lectin
FADD Fas-associated protein with death domain
GI gastrointestinal
GM-CSF granulocyte-macrophage colony-stimulating factor
HAT histone acetyltransferases
HIV human immunodeficiency virus
HSP heat shock protein
iDC immature DCs
IFN interferon
IKK inhibitor of NF-κB kinase
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IL interleukin
IL-1R interleukin-1 receptor
IP3 inositol triphosphate
IPS interferon-β promoter stimulator 1
IRS interferon regulatory factor
ITAM immunoreceptor tyrosine-based activatory motif
ITIM immunoreceptor tyrosine-based inhibitory motif
IκB inhibitor of NF-κB
JNK c-Jun N-terminal kinases
LBD ligand-binding domain
LDL low-density lipoproteins
LOX lectin-like oxidised LDL receptor
LPS lipopolysaccharide
mAb monoclonal antibody
MAH macrophage antigen H
Malt mucosa-associated lymphoid tissue lymphoma translocation
MAPK mitogen-activated protein kinase
MDA melanoma differentiation-associated protein
MDL DAP12-associating lectin
MICL myeloid inhibitory C-type-like lectin
Mincle macrophage-inducible C-type lectin
MyD myeloid differentiation primary response gene
NFAT nuclear factor of activated T-cells
NF-κB nuclear factor-κB
NIK NF-κB-inducing kinase
NK natural killer
NKC natural killer gene complex
NKG2D natural killer group 2member D
NLR nucleotide-oligomerisation domain-like receptor
NLRC NOD, leucine-rich repeat and CARD domain-containing protein
NLRP NOD, leucine-rich repeat and pyrin domain-containing protein
NOD nucleotide-oligomerisation domain
OxLDL oxidised low-density lipoproteins
PAMP pathogen-associated molecular pattern
PI3K phosphoinositide 3-kinase
PIP3 phosphatidylinositol-3,4,5-triphosphate
PKC protein kinase C
PLC phospholipase C
PRR pattern recognition receptor
RIG retinoic acid-inducible gene
RIP receptor-interacting serine/threonine-protein kinase
RLR retinoic acid-inducible gene-like receptor
ROS reactive oxygen species
RT-PCR reverse transcriptase-polymerase chain reaction
SARM sterile-alpha and armadillo-motif-containing protein
SH Src homology
SHIP SH2 domain-containing inositol phosphatases
SHP SH2-domain-containing protein tyrosine phosphatase
SIGNR SIGN-related
STAT signal transducer and activator of transcription
Syk spleen tyrosine kinase
TAK transforming growth factor β-activated kinase
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TGF transforming growth factor
TH T helper
TIR Toll/IL-1 receptor
TIRAP Toll-interleukin 1 receptor (TIR) domain-containing adaptor protein
TLR Toll-like receptor
TNF tumour necrosis factor
TRADD tumour necrosis factor receptor type 1-associated death domain protein
TRAF TNF receptor-associated factor
TRAM TRIF-related adaptor molecule
Tregs regulatory T cells
TRIF TIR-domain-containing adapter-inducing interferon-β
TxA2 thromboxin A2.
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